GSK’s antibiotic succeeds in late-stage gonorrhea trial with eye to addressing resistance
26 Feb 2024
Phase 3Clinical ResultQualified Infectious Disease Product
GSK’s oral antibiotic gepotidacin has hit the primary endpoint in a Phase III trial for urogenital gonorrhea, a growing public health concern due to increased rates and emerging resistance.
The EAGLE-1 trial set gepotidacin against ceftriaxone plus azithromycin in around 600 subjects with uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae. The drug candidate demonstrated non-inferiority in the trial’s primary endpoint, microbiological response at the Test-of-Cure visit three to seven days after treatment.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.